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(composite: any DVT, non-fatal PE, all-cause mortality) by 49%
and symptomatic VTE by 66% versus enoxaparin. A cost–utility
model (health care perspective) assessed the cost-effectiveness
over ﬁve years following TKR of rivaroxaban versus enoxaparin
in the UK and Spain, two large European countries with different
approaches to post-surgical prophylaxis and patient manage-
ment. The model was populated using RECORD3 data. Pub-
lished epidemiological and clinical data estimated risks of VTE
and post-thrombotic syndrome beyond the trial period. Costs
were derived from published local sources and expressed in
pounds (£) for the UK and euros (€) for Spain. Utilities were
taken from a systematic literature review. Potential savings from
oral administration were included in the UK analysis only, as in
Spain, drug administration costs are included in hospitalisation
charges. RESULTS: The model showed rivaroxaban produced
improved health outcomes and cost savings versus enoxaparin in
the UK and Spain (dominance). Improved health outcomes were
similar across both countries, while rivaroxaban produced cost
savings of £89.15 per patient in the UK and €144.93 in Spain.
Savings were driven by reduced costs of treating symptomatic
VTE and associated long term complications, as well as oral
outpatient administration in the UK. In both countries, pro-
babilistic sensitivity analyses showed rivaroxaban maintained
dominance versus enoxaparin in more than 99% of cases.
CONCLUSIONS: Rivaroxaban is cost-effective following TKR
within the different health care systems of both these two major
European countries.
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OBJECTIVES: Assess cost-effectiveness of 35 days rivaroxaban,
an oral direct Factor Xa inhibitor, versus 12 days and 35 days
subcutaneous enoxaparin for prevention of venous throm-
boembolism (VTE) following total hip replacement (THR).
METHODS: Rivaroxaban regimens were compared with dif-
ferent enoxaparin regimens following THR in two large ran-
domized controlled trials. RECORD1 compared 35 days
prophylaxis with rivaroxaban or enoxaparin, while RECORD2
compared 35 days rivaroxaban with 12 days enoxaparin. While
the ACCP and NICE recommend up to 35 days prophylaxis in
higher-risk patients after THR, a shorter duration is often used
in the UK and elsewhere. In RECORD1, rivaroxaban reduced
total VTE (composite: any DVT, non-fatal PE, all-cause mor-
tality) by 70% versus enoxaparin after 35 days prophylaxis,
although the reduction in symptomatic VTE with rivaroxaban
was not statistically signiﬁcant. In RECORD2, rivaroxaban
reduced total VTE by 79% and symptomatic VTE by 80%
versus 12 days enoxaparin. A cost–utility model (health care
perspective) assessed cost-effectiveness of rivaroxaban versus
both durations of enoxaparin over the ﬁve years following
surgery. The model was populated by RECORD1-2 data while
published epidemiological and clinical data estimated risks of
VTE and post-thrombotic syndrome beyond the trial period.
Costs (2008 pounds [£]) were derived from published sources.
Utilities were taken from a systematic literature review. Poten-
tial savings associated with administration and monitoring were
also included. RESULTS: Thirty-ﬁve days rivaroxaban domi-
nated 35 days enoxaparin, yielding improved health outcomes
(QALYs) and savings of £67.82 per patient. Savings were
driven mainly by reduced outpatient administration costs.
Rivaroxaban also dominated 12 days enoxaparin, with a
QALY gain of 0.022 and savings of £22.38. Probabilistic
sensitivity analyses showed dominance in 98% of cases versus
35 days enoxaparin and 55% versus 12 days enoxaparin.
CONCLUSIONS: Rivaroxaban is cost-effective versus both
12 and 35 days enoxaparin, for prevention of VTE following
THR in the UK.
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OBJECTIVES: Assess economic impact of rivaroxaban, an oral
direct Factor Xa inhibitor, in VTE prevention following total hip
and total knee replacement (THR/TKR). METHODS: Rivaroxa-
ban regimens were compared with enoxaparin regimens for VTE
prevention in three large randomized controlled trials. For THR,
35 days rivaroxaban was compared with 35 days enoxaparin
(RECORD1), or 12 days enoxaparin (RECORD2). RECORD3
compared rivaroxaban and enoxaparin for 12 days following
TKR. Rivaroxaban reduced total VTE (composite: any DVT,
non-fatal PE, all-cause mortality) following THR by 70% versus
35 days enoxaparin and 79% versus 12 days enoxaparin. Fol-
lowing TKR, rivaroxaban reduced total VTE by 49% versus
enoxaparin. Bleeding was similar with both agents. An economic
model (health care perspective) assessed clinical and economic
consequences of rivaroxaban versus enoxaparin for ﬁve years
following surgery. The model was populated using RECORD
1–3 data and calculated outcomes for total VTE and symptom-
atic VTE. Cost results for the latter are presented here. Incidences
for VTE and post-thrombotic syndrome after the trials were
estimated from published data. Costs, (2008 euros [€]), were
derived from published Italian sources. As the Italian rivaroxa-
ban price is not published, rivaroxaban and enoxaparin costs
were excluded. RECORD 1–3 data were combined to estimate
costs and consequences of rivaroxaban versus enoxaparin for
THR/TKR. RESULTS: Overall improvement in outcomes with
rivaroxaban following THR and TKR was 0.021 symptomatic
VTE events per patient undergoing surgery; non-drug costs were
reduced by €81.32. These were consistent with individual THR
and TKR results when the RECORD trials were analysed sepa-
rately. In 2004, 96,000 THR and TKR were performed in Italy.
Rivaroxaban could yield total annual non-drug cost savings of
approximately €7.6 million. CONCLUSIONS: Rivaroxaban
thromboprophylaxis following THR or TKR may improve
health outcomes and reduce non-drug costs versus existing
approaches. Hence rivaroxaban may represent a more efﬁcient
approach to VTE prophylaxis in Italy.
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OBJECTIVES: Previous European research has shown that lap-
aroscopic surgery is frequently complicated by the need for adhe-
siolysis due to adhesions caused by previous surgery. In Europe
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this increases surgery time and post-operative stay, and in the
longer-term can adversely affect patient outcomes. As part of a
program to assess the burden of adhesions in the USA we
assessed the short-term additional costs of common laparoscopic
gynecological operations including adhesiolysis. METHODS:
The Premier database provides detailed hospital cost accounting
data from over 500 centers across the USA. A cohort of patients
undergoing gynecological laparoscopic surgery between 2004–
2006, including ovarian procedures, was selected by ICD9-CM
and identiﬁed on discharge. Those patients undergoing adhesi-
olysis secondary to another procedure were also identiﬁed. All
discharges were classiﬁed as inpatient or outpatient. Mean total
costs, surgery cost and mean length of stay (LOS) were deter-
mined for each procedure and sub-group, with and without
adhesiolysis. Regression analyses were undertaken to test for
signiﬁcant differences between procedures, with and without
adhesiolysis. RESULTS: A total of 7928 inpatient and 6820
outpatient discharges for laparoscopic ovarian procedures (with
total costs) were identiﬁed. 30.8% and 33.6% included adhesi-
olysis. The additional costs of adhesiolysis accounted for an extra
5.3% ($328) and 6.9% ($215) of total costs. Surgical costs
accounted for 23.7% ($78) and 27.5% ($59) of additional costs.
Both total and surgery costs were signiﬁcantly higher for the
same procedure with adhesiolysis compared to that without
(P < 0.0001). The mean LOS for inpatients was signiﬁcantly
longer with adhesiolysis (2.35 d) than without (2.02 d),
(P < 0.0001). CONCLUSIONS: This study conﬁrms previous
European research that adhesiolysis occurs in approximately
one third of ovarian laparoscopic procedures and results in
additional hospital costs and longer LOS. While the long-term
outcome burden of adhesiolysis has been demonstrated by the
SCAR study in Scotland, the impact in the USA needs further
exploration.
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OBJECTIVES: PRINEO® Skin Closure System (PRINEO) offers
effective and safe wound closure compared to conventional
suture techniques i.e. Standard of Care (SOC). The aim of this
study was to evaluate differences in health resource utilization
attributable to use of PRINEO vs. SOC for abdominoplasty
surgery. METHODS: A time and motion study was conducted in
one centre in The Netherlands. Trained centre staff collected ten
observations (ﬁve for PRINEO and ﬁve for SOC) following the
patient from surgery through post-op care. Data Observation
Forms were designed based on information obtained from staff
interviews. Surgical wound closure and management activities
were observed for which differences in time and resource use
between PRINEO and SOC were expected: incision closure time,
dressing applications, and dressing changes (during admission
and post-discharge return). RESULTS: Average time for skin
layer closure was 1.29 min for PRINEO vs. 17.95 min for SOC.
Average wound length was 48 cm vs. 49 cm, respectively. This
translates into a speed of closure increase from 2.73 cm/min
(SOC) to 37.09 cm/min (PRINEO). Average time for wound
closure (dermal and skin layer) was 24.85 min with PRINEO
compared to 31.83 min for SOC. The SOC treatment arm
incurred 2.19 min and 3.07 min for dressing application and
post-op dressing changes respectively. PRINEO did not require
any dressing. Additionally, use of PRINEO resulted in elimina-
tion of suture closure materials which on average included 2.4
strands of Monocryl 2-0 sutures, 5.7 adhesive dressings, 17.4
strips of adhesive tapes, and 9.3 gauze swabs. One PRINEO unit
was required. CONCLUSIONS: The use of PRINEO resulted in
increased skin closure speed and avoided ﬁnal skin layer closure
and aftercare management of the wound in terms of dressing
application and changes. Concomitant to the savings in person-
nel time was a reduction in surgical supply materials.
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OBJECTIVES: PRINEO® Skin Closure System (PRINEO) offers
effective and safe wound closure compared to conventional
suture techniques i.e. Standard of Care (SOC). The aim of this
study was to evaluate differences in health resource utilization
attributable to PRINEO vs. SOC for abdominoplasty surgery.
METHODS: A time and motion study was conducted in one
centre in Germany. Trained centre staff collected ten observations
(ﬁve for PRINEO and ﬁve for SOC) following the patient from
surgery through post op care. Data Observation Forms were
designed based on information obtained from staff interviews.
Surgical wound closure and management activities were
observed for which differences in time and resource use between
PRINEO and SOC were expected: incision closure time, dressing
applications, and dressing changes (during admission and post-
discharge return). RESULTS: Average time for skin layer closure
was 2.11 min for PRINEO vs. 13.01 min for SOC. Average
wound length was 46.4 cm vs. 52.6 cm, respectively. This
translates into a speed of closure of 4.04 cm/min for SOC vs.
21.97 cm/min with PRINEO. Average time for wound closure
(dermal and skin layer) was 24.85 min (PRINEO) compared to
34.05 min (SOC). The SOC treatment arm incurred 2.94 min
and 4.32 min for dressing application and post-operative dress-
ing changes, respectively. PRINEO did not require any dressing.
Additionally, use of PRINEO resulted in elimination of suture
closure materials which on average included 2 strands of Monoc-
ryl 2-0 sutures, 2 polydioxanone sutures, 13.6 Cosmopor adhe-
sive dressings, 12 strips of adhesive tapes, and 7.4 gauze swabs.
One PRINEO unit was required. CONCLUSIONS: The use of
PRINEO resulted in increased skin closure speed and avoided
ﬁnal skin layer closure and aftercare management of the wound
in terms of dressing application and changes. Concomitant to the
savings in personnel time was a reduction in surgical supply
materials.
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OBJECTIVES: To reﬂect various approaches for organ pro-
curement such as altruism, altruism combined with ﬁnancial
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